LA JOLLA, CA —Pancreatic cancer is one of the deadliest cancers—only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall of fibrosis, or scar tissue, that surrounds most pancreatic tumors and makes it hard for drugs...
treatment News
SHANGHAI and CLINTON, N.J. — HuidaGene Therapeutics today announced the U.S. FDA granted Rare Pediatric Drug Designation (RPDD) to HG302, a novel CRISPR-Cas12 DNA-editing therapy, to treat Duchenne muscular dystrophy (DMD), affecting 1 in ~5,000 newborn boys. Unlike the in-vivo use of Cas9 system with limited genome-editing efficiency, high occurrence...
Human fibrinogen concentrate (HFC) has favorable pharmacokinetics for adult, adolescent, and pediatric patients with congenital fibrinogen deficiency (CFD), according to the results of open-label studies presented at the 2021 American Society of Pediatric Hematology/Oncology (ASPHO) meeting. The prospective studies FORMA-01, FORMA-02, and FORMA-04 looked at efficacy, safety, and dosing of...
ROCKVILLE, Md. — Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of results from a long-term Phase 2 continuation trial showing that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares, and was generally well tolerated...
BURLINGAME, Calif. – Humanigen, Inc. (Nasdaq:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered® antibody, ifabotuzumab, in patients with glioblastoma multiforme...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — HUTCHMED (China) Limited announced that the New Drug Application for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a...
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J. — HUTCHMED (China) Limited today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). ELUNATE® is a selective oral inhibitor of...
This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (A TLL) SAN DIEGO – HUYABIO International, the leader in accelerating the global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R)...
INDIANAPOLIS — Clinical research led by Indiana University School of Medicine investigators and their collaborators in Uganda has revealed that hydroxyurea significantly reduces infections in children with sickle cell anemia. Their latest findings enhance strong evidence of hydroxyurea’s effectiveness and could ultimately reduce death in children in Africa, the continent...
Hyper-cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus rituximab (hyper-CVAD-R) can prevent central nervous system (CNS) relapse in patients with Burkitt leukemia/lymphoma (BL) or high-grade B-cell lymphoma (HGBL), according to a study published in Blood Advances. The retrospective study included 79 patients with newly diagnosed BL (n=54) or HGBL (n=25) who were treated...